Marker Therapeutics Inc (MRKR)

[ridinbulls]

What I like is the current platform is in oncology but the technology has potential to even be crossed over into infectious disease.

From the company website(also the acronym for why we are called TAP)....

TAP Vector Expression Platform Antigen System TAP (Transporters associated with Antigen Processing) is a central component of the immune system responsible for the processing of antigens and their subsequent presentation to the body’s immune system. TAP-based products have unique and broad application as vaccines for the treatment of both cancer and infectious disease.

....and

In the treatment of infectious disease the use of the company’s TAP technology can make vaccines for microbial pathogens significantly more effective. In animal models vaccines (e.g.smallpox) in the presence of TAP vaccines were 100-1000 times more effective or potent. This offers a highly sought after solution to situations where in a pandemic outbreak like bird flu or H1N1 or a bioterrorism threat, vaccines are insufficient to meet demand. It also means that the amount of vaccine required per dose would be significantly reduced and the often harmful side effects of those vaccines would be substantially reduced or eliminated.

Infectious Disease and National Preparedness is another very significant market and ideal therapeutic area for the TPIV vaccine conjugate. Along with novel peptides and the PolyStart expression system the TPIV vaccine platform can address multiple infectious diseases as well as pandemic and biodefense threats. Our current Smallpox vaccine study at Mayo Clinic has already shown significant benefits over the current vaccine stockpile. It is naturally processed and peptide based, making it safer, longer lasting, cheaper and as effective (in animal studies) as the current product stockpile. The last DHHS contract for a smallpox vaccine stockpile was worth up to $2.8 Billion.